drugset / Trial / NCT03342417
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Safety and tolerability of combination of Nivolumab and Ipilimumab will be studied in patients with 3 different types of cancers in 3 parts of the study, as shown below: Part 1 - Neoadjuvant Therapy of Breast Cancer; Part 2 - Therapy of Ovarian Cancer; and Part 3 - Therapy of Gastric Cancer.
Timeline
- Start
- 2018-02-14
- Primary completion
- 2019-05-29
- Completion
- 2019-05-29
Outcome
Outcome not reported
Stopped (Enrollment): “Slow patient accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |